SYnAbs' vision is to fill the gap on the marketplace for innovative mAbs against poor immunogenic compounds and complex antigens. Targeting steroids, peptides, small molecules, toxins, lipids and polysaccharides (on fungi and bacteria), SYnAbs has developed a strong expertise in immunology to break immunotolerance in rat and guinea pig species to generate unique monoclonal antibodies of extreme specificity and higher affinity.

SYnAbs SA is currently involved in the production of rat monoclonal antibodies, serving CROs (mAb and custom immunoassays) and a large catalogue of secondary monoclonal antibodies (more than a hundred secondary anti-immunoglobulins) and unique primary monoclonal antibodies

SynAbs, Belgium